These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 23296069)

  • 1. The disconnect between phase II and phase III trials of drugs for heart failure.
    Vaduganathan M; Greene SJ; Ambrosy AP; Gheorghiade M; Butler J
    Nat Rev Cardiol; 2013 Feb; 10(2):85-97. PubMed ID: 23296069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New and emerging drug therapies for the management of acute heart failure.
    Krum H; Liew D
    Intern Med J; 2003 Nov; 33(11):515-20. PubMed ID: 14656255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newer approaches to the pharmacological management of heart failure.
    Rauch H; Motsch J; Böttiger BW
    Curr Opin Anaesthesiol; 2006 Feb; 19(1):75-81. PubMed ID: 16547437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heart failure. Tardy but intact--publication of REVIVE trial results welcomed.
    Cully M
    Nat Rev Cardiol; 2013 Jun; 10(6):297. PubMed ID: 23609172
    [No Abstract]   [Full Text] [Related]  

  • 5. The development of new medical treatments for acute decompensated heart failure.
    Teerlink JR
    Heart Fail Monit; 2002; 2(4):129-37. PubMed ID: 12634887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure.
    Teerlink JR
    Am Heart J; 2003 Feb; 145(2 Suppl):S26-33. PubMed ID: 12594449
    [No Abstract]   [Full Text] [Related]  

  • 7. Levosimendan: from basic science to clinical trials.
    Rognoni A; Lupi A; Lazzero M; Bongo AS; Rognoni G
    Recent Pat Cardiovasc Drug Discov; 2011 Jan; 6(1):9-15. PubMed ID: 21208157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence-based pharmacotherapies used in the postdischarge phase are associated with improved one-year survival in senior patients hospitalized with heart failure.
    Qin X; Hung J; Knuiman M; Teng TK; Briffa T; Sanfilippo FM
    Cardiovasc Ther; 2018 Dec; 36(6):e12464. PubMed ID: 30126048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the recombinant form of the natural human B-type natriuretic peptide and levosimendan on pulmonary hyperventilation and chemosensivity in heart failure.
    Bocchi EA; Moura LZ; Issa VS; Cruz F; Carvalho VO; Guimarães GV
    Cardiovasc Ther; 2013 Apr; 31(2):100-7. PubMed ID: 21884030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
    Konstam MA; Gheorghiade M; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
    JAMA; 2007 Mar; 297(12):1319-31. PubMed ID: 17384437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure.
    Greene SJ; Mentz RJ; Fiuzat M; Butler J; Solomon SD; Ambrosy AP; Mehta C; Teerlink JR; Zannad F; O'Connor CM
    Circulation; 2018 Sep; 138(10):1039-1053. PubMed ID: 30354535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial).
    Shah AN; Mentz RJ; Gheorghiade M; Kwasny MJ; Fought AJ; Zannad F; Swedberg K; Maggioni AP; Konstam MA
    Am J Cardiol; 2012 Dec; 110(12):1803-8. PubMed ID: 22999071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
    Gheorghiade M; Konstam MA; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
    JAMA; 2007 Mar; 297(12):1332-43. PubMed ID: 17384438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure).
    Greene SJ; Hernandez AF; Sun JL; Metra M; Butler J; Ambrosy AP; Ezekowitz JA; Starling RC; Teerlink JR; Schulte PJ; Voors AA; Armstrong PW; O'Connor CM; Mentz RJ
    Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27623769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levosimendan in acute decompensated heart failure: systematic review and meta-analysis.
    Ribeiro RA; Rohde LE; Polanczyk CA
    Arq Bras Cardiol; 2010 Aug; 95(2):230-7. PubMed ID: 20549133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure.
    Ter Maaten JM; Valente MA; Damman K; Cleland JG; Givertz MM; Metra M; O'Connor CM; Teerlink JR; Ponikowski P; Bloomfield DM; Cotter G; Davison B; Subacius H; van Veldhuisen DJ; van der Meer P; Hillege HL; Gheorghiade M; Voors AA
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27266853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term effect of levosimendan on free light chain kappa and lambda levels in patients with decompensated chronic heart failure.
    Kurt IH; Yavuzer K; Batur MK
    Heart Vessels; 2010 Sep; 25(5):392-9. PubMed ID: 20676961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levosimendan: a calcium-sensitizing agent for the treatment of patients with decompensated heart failure.
    Lehtonen L
    Curr Heart Fail Rep; 2004 Sep; 1(3):136-44. PubMed ID: 16036037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological therapy of acute cardiogenic pulmonary oedema in the emergency department.
    Graham CA
    Emerg Med Australas; 2004 Feb; 16(1):47-54. PubMed ID: 15239755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.
    O'Connor CM; Miller AB; Blair JE; Konstam MA; Wedge P; Bahit MC; Carson P; Haass M; Hauptman PJ; Metra M; Oren RM; Patten R; Piña I; Roth S; Sackner-Bernstein JD; Traver B; Cook T; Gheorghiade M;
    Am Heart J; 2010 May; 159(5):841-849.e1. PubMed ID: 20435194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.